Oncolytics Biotech Inc
TSX:ONC
Oncolytics Biotech Inc
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.
Financial Runway: Oncolytics ended Q1 2025 with $15.3 million in cash, providing runway through Q3 2025 and key milestones.
Clinical Progress: Pelareorep continues to show strong potential in multiple cancer types, with notable clinical results in metastatic breast, pancreatic, and anal cancers.
Breast Cancer Path Forward: Management anticipates the registrational trial for HR+/HER2- metastatic breast cancer will use progression-free survival as the primary endpoint, with discussions ongoing regarding optimal trial design.
Pipeline Validation: Two randomized Phase II studies demonstrated significant efficacy for pelareorep, including near doubling of survival outcomes compared to standard care.
Business Development: The company is actively pursuing both global and regional partnerships, leveraging recent data and a favorable safety profile to attract potential biopharma partners.
Share Purchase Agreement: A $20 million share purchase agreement with Alumni Capital provides flexible access to capital at Oncolytics’ discretion, extending its financial runway.
CEO Search: The CEO search remains active, with an announcement expected in the near future.
